Industry Update: Biotechnology
VRC is proud to release its latest industry report. The report provides a concise, insightful update on the Biotechnology industry including recent transactions, market multiples, company performance and purchase price allocation percentages.
I
ndustry Highlights
- On October 20, 2022, AbbVie completed the acquisition of DJS Antibodies Ltd for $255 million. DJS is focused on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs), and compliments AbbVie’s efforts to focus on specific transmembrane protein targets.
- On September 8, 2022, Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, announced the closing of a $32.7 million financing round. Current shareholders ARCH Venture Partners, Cowen Healthcare Investments, BVF Partners L.P., Biogen, Bristol Myers Squibb, Pfizer Ventures, Invus, Section 32, Samsara BioCapital, Alexandria Venture Investments and GT Healthcare all participated in the round.
